rhodojaponin III: from Rhododendron Molle G. Don; structure given in first source; RN given refers to (2beta,3beta,6beta,14R)-isomer; RN for cpd without isomeric designation not avail 7/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Rhododendron | genus | A plant genus of the family ERICACEAE.[MeSH] | Ericaceae | The heath plant family of the order Ericales, subclass Dilleniidae, class Magnoliopsida that are generally shrubs or small trees. Leaves are alternate, simple, and leathery; flowers are symmetrical with a 4- or 5-parted corolla of partly fused petals.[MeSH] |
| Rhododendron molle | species | [no description available] | Ericaceae | The heath plant family of the order Ericales, subclass Dilleniidae, class Magnoliopsida that are generally shrubs or small trees. Leaves are alternate, simple, and leathery; flowers are symmetrical with a 4- or 5-parted corolla of partly fused petals.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 135659019 |
| CHEBI ID | 186091 |
| MeSH ID | M0189566 |
| Synonym |
|---|
| rhodojaponin iii |
| 26342-66-5 |
| CHEBI:186091 |
| (1s,3r,4r,6r,8s,9s,10r,11r,14r,15r,17r)-5,5,10,15-tetramethyl-7-oxapentacyclo[12.2.1.01,11.04,9.06,8]heptadecane-3,4,10,15,17-pentol |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Rhodojaponin III (RJ-III) has been identified as the main pharmacological activity and toxic component of the herb; however, oral antinociception and mechanism of RJ-III have not yet been investigated." | ( Evaluation of Rhodojaponin III from Rhododendron molle G. Don on oral antinociceptive activity, mechanism of action, and subacute toxicity in rodents. Feng, Y; Liu, M; Sun, S; Wang, Y; Yang, J; Yang, Q; Zhang, J; Zhao, J, 2022) | 0.72 |
| "375 mg/kg and above may cause side effect after long-term oral administration." | ( Evaluation of Rhodojaponin III from Rhododendron molle G. Don on oral antinociceptive activity, mechanism of action, and subacute toxicity in rodents. Feng, Y; Liu, M; Sun, S; Wang, Y; Yang, J; Yang, Q; Zhang, J; Zhao, J, 2022) | 0.72 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Then, an LC-MS method was established to determine the rat plasma concentrations of three major rhodojaponins including rhodojaponin I, II and III (R-I, II and III) and was applied to pharmacokinetic study." | ( The integrated pharmacokinetics of major rhodojaponins correlates with the cardiotoxicity after oral administration of Rhododendri Mollis Flos extract in rats. Dong, LC; Li, HJ; Li, P; Luo, N; Ma, J; Song, W; Zhang, XH, 2014) | 0.4 |
| " The pharmacokinetic parameters (AUC0-t, AUC0-∞, t1/2, Tmax and Cmax) for R-I, II and III were markedly different, and the integrated pharmacokinetics was therefore converted to describe the holistic pharmacokinetic profiles of R-I, II and III, which correlated pretty well with cardiotoxicity." | ( The integrated pharmacokinetics of major rhodojaponins correlates with the cardiotoxicity after oral administration of Rhododendri Mollis Flos extract in rats. Dong, LC; Li, HJ; Li, P; Luo, N; Ma, J; Song, W; Zhang, XH, 2014) | 0.4 |
| " This study also highlighted the potential of integrated pharmacokinetics to provid a more comprehensive understanding of the relationship between the pharmacokinetic behaviors of traditional Chinese herbal medicine and its efficacy." | ( The integrated pharmacokinetics of major rhodojaponins correlates with the cardiotoxicity after oral administration of Rhododendri Mollis Flos extract in rats. Dong, LC; Li, HJ; Li, P; Luo, N; Ma, J; Song, W; Zhang, XH, 2014) | 0.4 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "08 h) and good oral bioavailability (73." | ( Pharmacokinetics, bioavailability and tissue distribution studies of rhodojaponin III in mice using QTRAP LC-MS/MS. Feng, Y; Liang, S; Ma, BL; Wu, F; Yang, QY; Zhang, JQ; Zhao, CC, 2019) | 0.51 |
| " Pharmacokinetic results showed that after intragastric administration in mice, the relative bioavailability of RJ-III@HACC-SLNs was 87." | ( Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo. Feng, Y; Liang, S; Liu, M; Sun, S; Yang, J; Yang, Q; Zhang, J; Zhao, J, 2022) | 0.72 |
| Class | Description |
|---|---|
| diterpene | A C20 terpene. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||